New | China’s Medisun enters into partnership deal with Mayo Clinic in United States

US hospital Mayo Clinic has entered into a partnership agreement with Chinese healthcare firm Medisun Holdings to collaborate on patient services and regenerative treatment research, a statement posted Monday morning to the stock exchange said.

“Mayo Clinic will provide health care consulting services to aid Medisun’s work providing high-quality medical services to patients in Hong Kong and mainland China. The two organizations will further collaborate to ensure efficient referral of patients from China to Mayo Clinic in the United States,” the announcement of the January 16 agreement from National Investments Fund said.

National Investments Fund holds a 30 per cent stake in Medisun, an investor in hospitals, medical centres and regenerative medical projects in greater China.

Mayo Clinic, one of the most prestigious hospitals in the US, was the first to discover C-Cure regenerative technology for the treatment of heart failure.

Medisun Holdings also invested in Belgian and French listed Cardio3 BioSciences via a wholly owned subsidiary. A joint venture company, Cardio3 BioSciences Asia Holdings Limited, has been formed between Medisun and Cardio3 BioSciences, for developing and promoting C-Cure treatments in China and Asia.

“The right to use this patented technology has been granted to Cardio3 BioSciences exclusively. This stem cell therapy is now under clinical trial testing (phase III) in Europe, and is entering clinical trial testing (phase III) in the US for the treatment of heart failure.”